Galantamine Hydrobromide
Product Images NDC 51990-111

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Galantamine Hydrobromide (NDC 51990-111). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Yabao Pharmaceutical Co., Ltd. Beijing, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (12 mg Tablet Label)

Label for Galantamine Hydrobromide Tablets, USP 12 mg, containing 60 tablets, by Yabao Pharmaceutical Co., Ltd. Beijing. The label includes dosage strength, storage instructions, warnings to keep out of reach of children, and manufacturer/distributor information. It also displays the NDC 51990-113-04 and a barcode.*

FDA Label Image

Principal Display Panel (4 mg Tablet Label)

Label for Galantamine Hydrobromide Tablets, USP 4 mg, containing 60 tablets. The label specifies the active ingredient strength and manufacturer, Yabao Pharmaceutical Co., Ltd. Beijing. It includes storage instructions, a barcode, and details on product distribution by Solco Healthcare US LLC.*

FDA Label Image

Principal Display Panel (8 mg Tablet Label)

Label for Galantamine Hydrobromide Tablets, USP 8 mg, showing a bottle containing 60 tablets, Rx only. The label includes dosage strength, storage instructions, manufacturer information for Yabao Pharmaceutical Co., Ltd. Beijing, and a barcode. Distributed by Solco Healthcare US LLC.*

FDA Label Image

Chemical Structure (Galantamine 01)

Chemical structure of the active ingredient Galantamine Hydrobromide, as shown in the molecular diagram with functional groups including hydroxyl (OH), methoxy (CH3O), and a hydrobromide (HBr) salt component.*

FDA Label Image

Image Description (Galantamine 02)

A line graph depicting the mean change from baseline in ADAS-Cog score over 21 weeks of treatment for placebo and Galantamine Hydrobromide doses of 8 mg/day, 16 mg/day, and 24 mg/day. The vertical axis represents cognitive improvement or decline, while the horizontal axis shows weeks of treatment. The graph illustrates varying treatment effects across the groups over time.*

FDA Label Image

Image Description (Galantamine 03)

A cumulative percentage plot showing ADAS-cog change from baseline on the x-axis and cumulative percentage of patients on the y-axis. The graph compares placebo with doses of 8 mg/day, 16 mg/day, and 24 mg/day, illustrating patient response distribution across different treatment levels.*

FDA Label Image

Image Description (Galantamine 04)

A bar chart depicting the percentage of patients with different CIBIC-plus ratings after treatment with Galantamine Hydrobromide at doses of 8 mg/day, 16 mg/day, 24 mg/day, and placebo. The categories on the x-axis are Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, and Markedly Worse, with the y-axis showing the percentage of patients.*

FDA Label Image

Image Description (Galantamine 05)

A line graph showing the mean change from baseline in ADAS-Cog score over 26 weeks of treatment for placebo, 24 mg/day, and 32 mg/day groups. The y-axis represents improvement or decline, and the x-axis shows weeks of treatment, with data points and error bars indicating changes at multiple time intervals.*

FDA Label Image

Image Description (Galantamine 06)

A line graph showing the cumulative percentage of patients plotted against ADAS-cog change from baseline in a clinical context. It compares three groups: placebo, 24 mg/day, and 32 mg/day dosing of Galantamine Hydrobromide, with changes ranging from -15 to +15 points on the ADAS-cog scale.*

FDA Label Image

Image Description (Galantamine 07)

A bar graph showing the distribution of patients according to CIBIC-plus Rating categories (Markedly Improved to Markedly Worse) compared across three groups: Placebo, 24 mg/day, and 32 mg/day. The y-axis represents the percentage of patients, indicating comparative patient outcomes by treatment group.*

FDA Label Image

Image Description (Galantamine 08)

A line graph showing the mean change from baseline in ADAS-Cog scores over 26 weeks of treatment. The graph compares three groups: placebo, 24 mg/day, and 32 mg/day. The scores for the drug groups (24 mg/day and 32 mg/day) show improvement, while the placebo group shows a decline over time.*

FDA Label Image

Image Description (Galantamine 09)

A line graph showing the cumulative percentage of patients plotted against ADAS-cog change from baseline on the x-axis. The graph compares three groups: placebo (open circles), 24 mg/day (filled squares), and 32 mg/day (filled triangles) of treatment. The lines illustrate the progression of cognitive change over a scale from -15 to +15 points, with markers indicating significant change thresholds at -10, -7, -4 points, and no change at zero.*

FDA Label Image

Image Description (Galantamine 10)

A bar chart depicting CIBIC-plus Rating results as percentages of patients. It compares three groups: Placebo, 24 mg/day, and 32 mg/day. The categories on the x-axis range from 'Markedly Improved' to 'Markedly Worse,' showing the distribution of patient outcomes for each treatment group.*

FDA Label Image

Image Description (Galantamine 11)

A line graph depicting mean change from baseline in ADAS-cog score over 0, 4, and 13 weeks of treatment comparing placebo and 24 or 32 mg/day doses of Galantamine Hydrobromide. The 24 or 32 mg/day group shows cognitive improvement, while the placebo group shows decline or no change, with error bars indicating ±SE.*

FDA Label Image

Image Description (Galantamine 12)

A cumulative percentage of patients graph comparing ADAS-cog change from baseline between placebo and a 24 or 32 mg/day dose of Galantamine Hydrobromide. The x-axis shows change from baseline scores, and the y-axis shows cumulative patient percentages. Lines represent placebo and active dose groups with markers and thresholds at -10, -7, -4 points and no change indicated.*

FDA Label Image

Image Description (Galantamine 13)

A bar chart depicting patient percentages across different CIBIC-plus Rating categories for placebo and 24 or 32 mg/day treatment groups. Categories range from markedly improved to markedly worse, showing variations in patient responses with no change being the most common outcome for both groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.